CompletedNot Applicable

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

United States1,027 participantsStarted 2014-06-02

Plain-language summary

The purpose of this study is to retrospectively evaluate the treatment patterns and AML-related key healthcare resource use among AML patients, stratified by FLT3 mutation status, intensive chemotherapy (IC) eligibility, and relapsed or refractory (R/R) status.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed diagnosis of AML but NOT acute promyelocytic leukemia (APL) * Known FLT3 mutation status * Under the care of the participating physician during the past 3 years OR from the initial diagnosis of AML * The medical records related to AML for the patient are available to the physician and can be abstracted for this study * The medical records contains complete information on treatments and AML-related hospitalization, including admission date, length of stay, and reason of hospitalization * Initiation date of first treatment after AML diagnosis OR date of being classified as relapsed from or being refractory to initial treatment (R/R) is between January 1, 2013 and December 31, 2015 Exclusion Criteria: * Not applicable

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Treatment patterns assessed by drugs initiated

Timeframe: Up to 3 years

Treatment patterns assessed by dosage

Timeframe: Up to 3 years

Treatment patterns assessed by duration of treatment

Timeframe: Up to 3 years

Treatment patterns assessed by whether remission was achieved.

Timeframe: Up to 3 years

Treatment patterns assessed by an event

Timeframe: Up to 3 years

AML-related healthcare resource use assessed by number of hospitalizations and lengths of ICU hospital stay

Timeframe: Up to 3 years

AML-related healthcare resource use assessed by number of emergency department (ED) visits

Timeframe: Up to 3 years

Trial details

NCT IDNCT03047083

SponsorAstellas Pharma Global Development, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2016-03-18

View on ClinicalTrials.gov More Acute Myeloid Leukemia (AML) trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Treatment patterns assessed by drugs initiated

Timeframe: Up to 3 years

Treatment patterns assessed by dosage

Timeframe: Up to 3 years

Treatment patterns assessed by duration of treatment

Timeframe: Up to 3 years

Treatment patterns assessed by whether remission was achieved.

Timeframe: Up to 3 years

Treatment patterns assessed by an event

Timeframe: Up to 3 years

AML-related healthcare resource use assessed by number of hospitalizations and lengths of ICU hospital stay

Timeframe: Up to 3 years

AML-related healthcare resource use assessed by number of emergency department (ED) visits

Timeframe: Up to 3 years